Literature DB >> 31485148

Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient Care.

Mark Redell, Glenn Tillotson.   

Abstract

Carbapenems are a primary treatment for infections from multidrug-resistant bacterial pathogens. To maintain their efficacy and control the emergence of further resistance, breakpoints that correspond to recommended doses with appropriate PK/PD target attainment are paramount.

Entities:  

Year:  2019        PMID： 31485148      PMCID： PMC6705486     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  15 in total

1.  Rationale for the 2010 Revised Susceptibility Breakpoints for Cephalosporins, Aztreonam, and Carbapenems for Enterobacteriaceae.

Authors:  Michael N Dudley
Journal:  J Pediatric Infect Dis Soc       Date:  2012-06       Impact factor: 3.164

2.  Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.

Authors:  Sarah M Bartsch; Susan S Huang; Kim F Wong; Rachel B Slayton; James A McKinnell; Daniel F Sahm; Krystyna Kazmierczak; Leslie E Mueller; John A Jernigan; Bruce Y Lee
Journal:  J Clin Microbiol       Date:  2016-08-31       Impact factor: 5.948

3.  Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing?

Authors:  Romney M Humphries; Janet A Hindler; Erin Epson; Sam Horwich-Scholefield; Loren G Miller; Job Mendez; Jeremias B Martinez; Jacob Sinkowitz; Darren Sinkowtiz; Christina Hershey; Patricia Marquez; Sandeep Bhaurla; Marcelo Moran; Lindsey Pandes; Dawn Terashita; James A McKinnell
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

4.  Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.

Authors:  Mariana Castanheira; Michael D Huband; Rodrigo E Mendes; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

Authors:  Twisha S Patel; Jerod L Nagel
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

Review 6.  The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida.

Authors:  Nasia Safdar; Dennis G Maki
Journal:  Ann Intern Med       Date:  2002-06-04       Impact factor: 25.391

7.  Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia.

Authors:  Anthony M Nicasio; Kathryn J Eagye; Effie L Kuti; David P Nicolau; Joseph L Kuti
Journal:  Pharmacotherapy       Date:  2010-05       Impact factor: 4.705

8.  Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.

Authors:  Sonia K Morgan-Linnell; Lauren Becnel Boyd; David Steffen; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

9.  In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

Authors:  Meredith A Hackel; Olga Lomovskaya; Michael N Dudley; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

10.  Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2017-04-17       Impact factor: 3.090
View more
  1 in total

Review 1.  The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.

Authors:  Mark Redell; Glenn S Tillotson
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.